Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Oct 30, 2008

Title: siRNA Molecules for the Treatment of Blood Vessels
Number: 20080260854
Filed: Jan. 19, 2006 PCT Filed: Jan. 19, 2006
Lead Inventor: Tobias Walker, Tuebingen University
The invention, the patent application’s abstract states, “relates to a nucleic acid molecule, a genetic construct, siRNA molecules, and a composition [comprising those molecules that] can be used for inhibition of the expression of endothelial adhesion molecules. The invention also relates to a device, which is coated with the aforementioned molecules, the composition or the construct, or contains them.”
The abstract adds that the invention “further relates to a corresponding use of the nucleic acid molecule, of the genetic construct, or of the siRNA molecules and a method of inhibition of the expression of adhesion molecules and a method of vessel grafting, lung transplantation, treatment of lung transplants, and a method of treatment of the open heart within the scope of cardioplegia.”

Title: Methods and Compositions for Enhancing Delivery of Double-Stranded RNA or a Double-Stranded Hybrid Nucleic Acid to Regulate Gene Expression in Mammalian Cells
Number: 20080261304
Filed: Jan. 11, 2008
Lead Inventor: Mohammad Ahmadian, Nastech Pharmaceutical (MDRNA)
The patent application, its abstract states, claims “a double-stranded RNA, preferably a small interfering RNA or an siHybrid, to which cholesterol moieties are linked.”

Title: Modified Nucleosides for RNA Interference
Number: 20080261905
Filed: Nov. 8, 2005 PCT Filed: Nov. 8, 2005
Lead Inventor: Piet Herdewijn, University of North Carolina, Chapel Hill
According to the patent application’s abstract, the invention “relates to the use of modified nucleotides and single- or double-stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl, and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The … invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single- or double-stranded oligonucleotides for RNA interference, antisense therapy, or other applications.”

Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Breast Cancer
Number: 20080261908
Filed: Jan. 31, 2008
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent application’s abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.